Overview: Tagrisso 80mg Tablet

AstraZeneca Pharma India Ltd is committed to improving access to essential cancer treatments like Tagrisso 80mg tablet for eligible patients. This support ensures that individuals who require osimertinib therapy can receive the medication more affordably.

Benefits of Tagrisso 80mg Tablet

Patients who enroll in the assistance will receive additional strips of Tagrisso 80mg tablet free of cost. For every 1 strip purchased, 2 extra strips are provided at no cost under this offer. This benefit is available exclusively to Indian patients who do not receive government reimbursement.

• Year 1: Receive 3 months of free medication after purchasing 9 months supply under the 1+2 scheme.

• Year 2 onwards: Get 6 months free when you obtain a 6-month supply.

This program provides significant cost savings over long-term treatment.

Eligibility Criteria

To qualify for the Tagrisso Patient Assistance Program (PAP), you must:

• Be an Indian citizen with valid identity proof.

• Have a valid prescription for Tagrisso 80mg tablet (osimertinib) from a licensed medical oncologist.

• Meet the program’s clinical and administrative guidelines.

Support and Contact Details

If you need help with the application or have questions, reach out to the patient support team at:

📧 Email: info@zyloxd.com

Introduction to Tagrisso 80mg Tablet

Tagrisso 80mg tablet contains osimertinib, a third-generation tyrosine kinase inhibitor used to treat non-small cell lung cancer (NSCLC) with EGFR mutations. It targets specific gene alterations (including T790M) that drive cancer growth.

This medication can be prescribed:

• As a first-line treatment for metastatic NSCLC with EGFR mutations.

• As adjuvant therapy post-surgery to reduce recurrence.

• In patients who have developed resistance to earlier-generation EGFR inhibitors.

It is not suitable for use in patients under 18 years of age.

How Tagrisso 80mg Tablet Works

Tagrisso acts by blocking EGFR signaling pathways, which slows or stops cancer cell growth. It can shrink tumors and improve progression-free survival in patients with certain genetic profiles.

Who Should Not Use Tagrisso 80mg Tablet

Avoid using this medicine if:

• You are allergic to osimertinib or any ingredients in the tablet.

• You have a history of interstitial lung disease, heart rhythm disorders, or severe skin reactions.

• You are pregnant or breastfeeding (unsafe for both).

Always inform your healthcare provider if you have kidney, liver, heart, or lung conditions before starting treatment.

Drug Interactions

Let your doctor know about all medications you are currently taking. Certain drugs (like strong CYP3A inhibitors or inducers) may reduce the effectiveness of Tagrisso 80mg tablet or increase side effects.

Safety Advice

Side Effects of Tagrisso 80mg

Common:

• Diarrhea, dry skin, fatigue

• Rash, nail changes, and mouth sores

• Muscle/joint pain, reduced appetite

Serious:

• Irregular heartbeat, chest pain

• Severe skin reactions

• Lung inflammation or pneumonia

• Eye problems or blurred vision

How to Use

• Take as directed by your oncologist—once daily, with or without food.

• Swallow the tablet whole with water.

• Do not crush, chew, or split the tablet.

• If you forget a dose, skip it if it’s close to your next dose. Never double up.

Storage Information

• Store at room temperature (below 25°C).

• Keep away from children and pets.

• Follow disposal instructions provided by your pharmacist.

FAQs about Tagrisso 80mg Tablet

Q1. Can I take Tagrisso with antibiotics?
Some antibiotics may interact with osimertinib. Always inform your doctor.

Q2. Does it cause hair loss?
Hair loss is rare but possible. Report any unusual hair fall.

Q3. What foods should I avoid?
Avoid grapefruit and its juice, as it may alter drug metabolism.

Q4. Is it safe for kidney patients?
Yes, generally safe, but inform your doctor if you have severe kidney issues.

Q5. Can Tagrisso shrink tumors?
Yes. Clinical studies show tumor shrinkage and improved progression-free survival.

Tagrisso 80mg Tablet – Key Facts

• Active ingredient: Osimertinib

• Therapeutic class: Antineoplastic

• Pharmacological class: EGFR tyrosine kinase inhibitor

• Primary use: Treatment of EGFR-mutant NSCLC

Disclaimer

This information is intended for educational purposes only and does not replace medical consultation. Please consult your doctor for personalized advice before starting or changing any treatment.